Fusion Pharmaceuticals Inc. (FUSN)
After hours:
| Previous Close | 21.42 |
| Open | 21.55 |
| Bid | 15.53 x 200 |
| Ask | 27.75 x 200 |
| Day's Range | 21.42 - 21.57 |
| 52 Week Range | 2.31 - 21.58 |
| Volume | |
| Avg. Volume | 2,104,967 |
| Market Cap | 1.824B |
| Beta (5Y Monthly) | -0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.45 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.67 |
ZacksFusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Fusion Pharmaceuticals (FUSN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksFusion (FUSN) to Report Q1 Earnings: Here's What to Expect
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
CNW GroupFusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that it has filed and is in the process of mailing the management information circular and proxy statement (the "Circular") and related materials for the special meeting (the "Meeting") of Fusion's shareholders (the "Shareholders") to approve the previously announced arrangement with AstraZeneca plc ("AstraZeneca") under
